KNIGHT THERAPEUTICS INC (GUD.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:GUD - CA4990531069 - Common Stock
6.05 CAD
+0.01 (+0.17%)
Overall GUD gets a fundamental rating of 4 out of 10. We evaluated GUD against 32 industry peers in the Pharmaceuticals industry. GUD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. GUD is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
GUD had negative earnings in the past year.
GUD had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: GUD reported negative net income in multiple years.
GUD had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
GUD has a Return On Assets of -0.33%. This is in the better half of the industry: GUD outperforms 62.50% of its industry peers.
Looking at the Return On Equity, with a value of -0.46%, GUD is in the better half of the industry, outperforming 65.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.33% | ||
| ROE | -0.46% | ||
| ROIC | N/A |
ROA(3y)-1.39%
ROA(5y)0.29%
ROE(3y)-1.78%
ROE(5y)0.26%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
GUD's Profit Margin has declined in the last couple of years.
GUD has a Gross Margin of 42.49%. This is comparable to the rest of the industry: GUD outperforms 56.25% of its industry peers.
GUD's Gross Margin has declined in the last couple of years.
GUD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 42.49% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-43.41%
PM growth 5Y-47.95%
GM growth 3Y-0.3%
GM growth 5Y-3.67%
2. Health
2.1 Basic Checks
GUD does not have a ROIC to compare to the WACC, probably because it is not profitable.
GUD has less shares outstanding than it did 1 year ago.
The number of shares outstanding for GUD has been reduced compared to 5 years ago.
Compared to 1 year ago, GUD has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.11 indicates that GUD is not a great score, but indicates only limited risk for bankruptcy at the moment.
GUD's Altman-Z score of 2.11 is amongst the best of the industry. GUD outperforms 84.38% of its industry peers.
The Debt to FCF ratio of GUD is 37.42, which is on the high side as it means it would take GUD, 37.42 years of fcf income to pay off all of its debts.
GUD has a Debt to FCF ratio (37.42) which is comparable to the rest of the industry.
GUD has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of GUD (0.11) is better than 65.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | 37.42 | ||
| Altman-Z | 2.11 |
ROIC/WACCN/A
WACC8.56%
2.3 Liquidity
A Current Ratio of 2.62 indicates that GUD has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.62, GUD is in the better half of the industry, outperforming 68.75% of the companies in the same industry.
A Quick Ratio of 1.68 indicates that GUD should not have too much problems paying its short term obligations.
The Quick ratio of GUD (1.68) is better than 78.13% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.62 | ||
| Quick Ratio | 1.68 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 93.10% over the past year.
Measured over the past years, GUD shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -13.46% on average per year.
The Revenue has grown by 18.70% in the past year. This is quite good.
The Revenue has been growing by 50.87% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)93.1%
EPS 3Y-25.31%
EPS 5Y-13.46%
EPS Q2Q%-4850%
Revenue 1Y (TTM)18.7%
Revenue growth 3Y15.1%
Revenue growth 5Y50.87%
Sales Q2Q%31.74%
3.2 Future
The Earnings Per Share is expected to grow by 55.65% on average over the next years. This is a very strong growth
Based on estimates for the next years, GUD will show a quite strong growth in Revenue. The Revenue will grow by 10.50% on average per year.
EPS Next Y-330.28%
EPS Next 2Y10.09%
EPS Next 3Y50.87%
EPS Next 5Y55.65%
Revenue Next Year14.81%
Revenue Next 2Y12.31%
Revenue Next 3Y8.59%
Revenue Next 5Y10.5%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for GUD. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 99.83, which means the current valuation is very expensive for GUD.
Based on the Price/Forward Earnings ratio, GUD is valued a bit cheaper than the industry average as 62.50% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 36.10. GUD is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 99.83 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of GUD is on the same level as its industry peers.
GUD's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 211.59 | ||
| EV/EBITDA | 12.57 |
4.3 Compensation for Growth
GUD's earnings are expected to grow with 50.87% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.09%
EPS Next 3Y50.87%
5. Dividend
5.1 Amount
GUD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:GUD (12/5/2025, 7:00:00 PM)
6.05
+0.01 (+0.17%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners14.23%
Inst Owner ChangeN/A
Ins Owners1.86%
Ins Owner ChangeN/A
Market Cap600.70M
Revenue(TTM)413.85M
Net Income(TTM)-3.49M
Analysts78.18
Price Target8.03 (32.73%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-753.57%
Min EPS beat(2)-815.07%
Max EPS beat(2)-692.08%
EPS beat(4)2
Avg EPS beat(4)-169.96%
Min EPS beat(4)-815.07%
Max EPS beat(4)461.4%
EPS beat(8)2
Avg EPS beat(8)-354.72%
EPS beat(12)5
Avg EPS beat(12)-190.89%
EPS beat(16)7
Avg EPS beat(16)-395.3%
Revenue beat(2)2
Avg Revenue beat(2)11.78%
Min Revenue beat(2)11.06%
Max Revenue beat(2)12.49%
Revenue beat(4)4
Avg Revenue beat(4)8.38%
Min Revenue beat(4)0.88%
Max Revenue beat(4)12.49%
Revenue beat(8)7
Avg Revenue beat(8)5.34%
Revenue beat(12)11
Avg Revenue beat(12)8.81%
Revenue beat(16)14
Avg Revenue beat(16)8.72%
PT rev (1m)0.92%
PT rev (3m)0.92%
EPS NQ rev (1m)-100%
EPS NQ rev (3m)-100%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)4.51%
Revenue NQ rev (3m)4.51%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 99.83 | ||
| P/S | 1.45 | ||
| P/FCF | 211.59 | ||
| P/OCF | 16.9 | ||
| P/B | 0.78 | ||
| P/tB | 2.02 | ||
| EV/EBITDA | 12.57 |
EPS(TTM)-0.02
EYN/A
EPS(NY)0.06
Fwd EY1%
FCF(TTM)0.03
FCFY0.47%
OCF(TTM)0.36
OCFY5.92%
SpS4.17
BVpS7.72
TBVpS2.99
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.33% | ||
| ROE | -0.46% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 42.49% | ||
| FCFM | 0.69% |
ROA(3y)-1.39%
ROA(5y)0.29%
ROE(3y)-1.78%
ROE(5y)0.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-43.41%
PM growth 5Y-47.95%
GM growth 3Y-0.3%
GM growth 5Y-3.67%
F-Score5
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | 37.42 | ||
| Debt/EBITDA | 1.93 | ||
| Cap/Depr | 58.99% | ||
| Cap/Sales | 7.91% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 80.91% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.62 | ||
| Quick Ratio | 1.68 | ||
| Altman-Z | 2.11 |
F-Score5
WACC8.56%
ROIC/WACCN/A
Cap/Depr(3y)40.08%
Cap/Depr(5y)130.51%
Cap/Sales(3y)6.77%
Cap/Sales(5y)24.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)93.1%
EPS 3Y-25.31%
EPS 5Y-13.46%
EPS Q2Q%-4850%
EPS Next Y-330.28%
EPS Next 2Y10.09%
EPS Next 3Y50.87%
EPS Next 5Y55.65%
Revenue 1Y (TTM)18.7%
Revenue growth 3Y15.1%
Revenue growth 5Y50.87%
Sales Q2Q%31.74%
Revenue Next Year14.81%
Revenue Next 2Y12.31%
Revenue Next 3Y8.59%
Revenue Next 5Y10.5%
EBIT growth 1Y-395.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year397.68%
EBIT Next 3Y80.27%
EBIT Next 5Y56.34%
FCF growth 1Y-63.88%
FCF growth 3YN/A
FCF growth 5Y23.85%
OCF growth 1Y56.3%
OCF growth 3Y-6.66%
OCF growth 5Y51.14%
KNIGHT THERAPEUTICS INC / GUD.CA FAQ
Can you provide the ChartMill fundamental rating for KNIGHT THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 4 / 10 to GUD.CA.
Can you provide the valuation status for KNIGHT THERAPEUTICS INC?
ChartMill assigns a valuation rating of 2 / 10 to KNIGHT THERAPEUTICS INC (GUD.CA). This can be considered as Overvalued.
What is the profitability of GUD stock?
KNIGHT THERAPEUTICS INC (GUD.CA) has a profitability rating of 2 / 10.
What is the financial health of KNIGHT THERAPEUTICS INC (GUD.CA) stock?
The financial health rating of KNIGHT THERAPEUTICS INC (GUD.CA) is 6 / 10.
Can you provide the expected EPS growth for GUD stock?
The Earnings per Share (EPS) of KNIGHT THERAPEUTICS INC (GUD.CA) is expected to decline by -330.28% in the next year.